Announcements Trials
Browse Landscape

Status

Not yet recruiting 3Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 29Observational 6

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Vascular Complications 1Oropharyngeal Neoplasms 1Neoplasms 1Mouth Neoplasms 1Immune-Related Adverse Events 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Surveys and Questionnaires 53Blood Specimen Collection 53Specimen Handling 28Radiotherapy 18Observation 18Interviews as Topic 13Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Drug Therapy 10Data Collection 10Biopsy 10Tomography, X-Ray Computed 9darolutamide 8Watchful Waiting 7Standard of Care 7ribociclib 6palbociclib 6Restraint, Physical 6Patient Reported Outcome Measures 6Magnetic Resonance Imaging 6Immune Checkpoint Inhibitors 6trastuzumab deruxtecan 5Positron-Emission Tomography 5Mass Screening 5Genetic Testing 5Esophagectomy 5Breath Tests 5Bevacizumab 5enzalutamide 4apalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Observational × Immune Checkpoint Inhibitors × 90 days × Clear all
NCT07593053 2026-05-22

PIPO

Vall d'Hebron Institute of Oncology

Completed
586 enrolled
Tumor-Agnostic

Neoplasms

NCT07535944 2026-04-17

ICI-Vasc

University Hospital, Rouen

Not yet recruiting
200 enrolled

Vascular Complications

NCT07359040 2026-03-12

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Peking University People's Hospital

Active not recruiting
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07466225 2026-03-12

HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

Peking University

Not yet recruiting
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07457099 2026-03-09

Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma

Zhujiang Hospital

Not yet recruiting
85 enrolled
Head & Neck

Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07453342 2026-03-06

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

Peking Union Medical College Hospital

Recruiting
500 enrolled

Immune-Related Adverse Events

Data powered by HemOnc (CC BY 4.0) Colophon âš¡